|
FR2697752B1
(fr)
|
1992-11-10 |
1995-04-14 |
Rhone Poulenc Rorer Sa |
Compositions antitumorales contenant des dérivés du taxane.
|
|
US6214388B1
(en)
*
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
|
US6210707B1
(en)
*
|
1996-11-12 |
2001-04-03 |
The Regents Of The University Of California |
Methods of forming protein-linked lipidic microparticles, and compositions thereof
|
|
KR19990029749A
(ko)
*
|
1997-09-17 |
1999-04-26 |
미우라 아끼라 |
2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
|
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US6410328B1
(en)
*
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
|
ATE271376T1
(de)
*
|
1998-02-23 |
2004-08-15 |
Cilag Ag Int |
Liposomale erythropoietin-dispersion
|
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
|
AU1678900A
(en)
*
|
1998-08-11 |
2000-03-06 |
All India Institute Of Medical Sciences |
A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
|
|
JP2002526422A
(ja)
*
|
1998-10-02 |
2002-08-20 |
ウィンディー ヒル テクノロジー インコーポレイテッド |
乳癌の同定、診断、及び治療の方法
|
|
US20030049262A1
(en)
*
|
1998-10-02 |
2003-03-13 |
Susan Love |
Methods for identification, diagnosis, and treatment of breast cancer
|
|
WO2000054807A1
(en)
*
|
1999-03-17 |
2000-09-21 |
Mitsubishi Chemical Corporation |
Ligand-bonded complex
|
|
US6333348B1
(en)
*
|
1999-04-09 |
2001-12-25 |
Aventis Pharma S.A. |
Use of docetaxel for treating cancers
|
|
EP1645289A1
(en)
|
1999-05-07 |
2006-04-12 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
|
ES2329437T3
(es)
|
1999-06-25 |
2009-11-26 |
Genentech, Inc. |
Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
|
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
GB9915074D0
(en)
*
|
1999-06-28 |
1999-08-25 |
Cortecs Plc |
Ligand-binding composition
|
|
KR20110008112A
(ko)
|
1999-08-27 |
2011-01-25 |
제넨테크, 인크. |
항-ＥｒｂＢ2 항체 투여 치료 방법
|
|
AU2136501A
(en)
*
|
1999-12-10 |
2001-06-18 |
Celator Technologies Inc. |
Lipid carrier compositions with protected surface reactive functions
|
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
|
MXPA02010011A
(es)
|
2000-04-11 |
2003-04-25 |
Genentech Inc |
Anticuerpos multivalentes y usos para los mismos.
|
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
|
CN109395082A
(zh)
|
2000-05-19 |
2019-03-01 |
杰南技术公司 |
用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
|
EP2052742A1
(en)
|
2000-06-20 |
2009-04-29 |
Biogen Idec Inc. |
Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
|
|
PL363618A1
(en)
*
|
2000-11-09 |
2004-11-29 |
Neopharm, Inc. |
Sn-38 lipid complexes and methods of use
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
HUP0101480A2
(hu)
*
|
2001-04-11 |
2004-01-28 |
István Horváth |
Eljárás koleszterinből nyerhető baktérium-méretű partikulák előállítására
|
|
AU2002305452A1
(en)
*
|
2001-05-08 |
2002-11-18 |
Emory University |
Regulating immine responses using dendritic cells
|
|
WO2003030864A1
(en)
*
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
EP2000545B1
(en)
|
2001-06-20 |
2011-08-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of lung tumor
|
|
EP2153843B1
(en)
|
2001-09-18 |
2012-08-15 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US20030228305A1
(en)
|
2002-01-02 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
AU2003215254A1
(en)
|
2002-02-13 |
2003-09-04 |
Immunology Laboratories, Inc. |
Compositions and methods for treatment of microbial infections
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
MXPA04010092A
(es)
|
2002-04-16 |
2004-12-13 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
|
KR100470535B1
(ko)
*
|
2002-06-27 |
2005-02-22 |
재단법인서울대학교산학협력재단 |
유피에이 항체 부착 이뮤노리포좀
|
|
DK2263691T3
(da)
|
2002-07-15 |
2012-10-22 |
Hoffmann La Roche |
Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4)
|
|
AU2003262650B2
(en)
|
2002-08-14 |
2009-10-29 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
|
AU2003296897A1
(en)
*
|
2002-08-20 |
2004-05-04 |
Neopharm, Inc. |
Pharmaceutical formulations of camptothecine derivatives
|
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
|
DK2364996T3
(en)
|
2002-09-27 |
2017-02-06 |
Xencor Inc |
Optimized Fc variants and methods for their formation
|
|
AU2003300280A1
(en)
*
|
2002-12-19 |
2004-07-14 |
Alza Corporation |
Method of treating angiogenic tissue growth
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
HRP20090325T1
(en)
|
2003-04-09 |
2009-07-31 |
Genentech |
Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
|
|
CA2530284A1
(en)
|
2003-07-08 |
2005-02-03 |
Genentech, Inc. |
Il-17 a/f heterologous polypeptides and therapeutic uses thereof
|
|
US20070148170A1
(en)
|
2005-10-03 |
2007-06-28 |
Desjarlais John R |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
WO2005037858A2
(en)
*
|
2003-10-16 |
2005-04-28 |
University Of Massachusetts |
Template-directed assembly of receptor signaling complexes
|
|
WO2005040163A1
(en)
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Heterocyclic compounds that block the effects of advanced glycation end products (age)
|
|
US20050147664A1
(en)
*
|
2003-11-13 |
2005-07-07 |
Elan Pharma International Ltd. |
Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
|
|
ES2472690T3
(es)
|
2003-11-17 |
2014-07-02 |
Genentech, Inc. |
Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
|
|
DE602005018325D1
(de)
|
2004-02-19 |
2010-01-28 |
Genentech Inc |
Antikörper mit korrigierten cdr
|
|
WO2006074418A2
(en)
|
2005-01-07 |
2006-07-13 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
|
CA2566007C
(en)
|
2004-05-03 |
2013-09-24 |
Hermes Biosciences, Inc. |
Drug delivery liposomes containing anionic polyols or anionic sugars
|
|
CN106075435A
(zh)
|
2004-06-04 |
2016-11-09 |
健泰科生物技术公司 |
用于治疗多发性硬化的方法
|
|
SI2471813T1
(sl)
|
2004-07-15 |
2015-03-31 |
Xencor, Inc. |
Optimirane Fc variante
|
|
JP4433918B2
(ja)
*
|
2004-07-15 |
2010-03-17 |
コニカミノルタエムジー株式会社 |
画像形成方法
|
|
CN101023182B
(zh)
|
2004-07-26 |
2013-04-17 |
健泰科生物技术公司 |
调节肝细胞生长因子活化的方法和组合物
|
|
AU2005295072A1
(en)
*
|
2004-10-08 |
2006-04-20 |
Alza Corporation |
Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
WO2006052767A2
(en)
*
|
2004-11-05 |
2006-05-18 |
Inex Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal camptothecin formulations
|
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
|
KR100651728B1
(ko)
*
|
2004-11-10 |
2006-12-06 |
한국전자통신연구원 |
정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
|
|
JP4652414B2
(ja)
|
2004-11-12 |
2011-03-16 |
ゼンコー・インコーポレイテッド |
ＦｃＲｎとの変化した結合を有するＦｃ変異体
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US20090148385A1
(en)
*
|
2004-11-19 |
2009-06-11 |
Koninklijke Philips Electronics, N.V. |
Ultrasound Contrast Agents For Molecular Imaging
|
|
BRPI0518104B8
(pt)
|
2005-01-21 |
2021-05-25 |
Genentech Inc |
artigo industrializado e uso de anticorpo her2
|
|
KR20070100968A
(ko)
*
|
2005-02-09 |
2007-10-15 |
제넨테크, 인크. |
매트릭스 메탈로프로테아제 길항제를 사용한, ｈｅｒ2박리의 억제
|
|
CN101163503B
(zh)
|
2005-02-23 |
2013-05-08 |
健泰科生物技术公司 |
使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
|
|
US20060204505A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
|
RU2007137489A
(ru)
|
2005-03-10 |
2009-04-20 |
Дженентек, Инк. (Us) |
Способы и композиции для модуляции целостности сосудов
|
|
JP2008536944A
(ja)
*
|
2005-04-22 |
2008-09-11 |
アルザ・コーポレーシヨン |
Ｈｅｒ２細胞受容体を標的とするためのイムノリポソーム組成物
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
WO2006132788A2
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
|
WO2007005754A2
(en)
*
|
2005-07-01 |
2007-01-11 |
Alza Corporation |
Liposomal delivery vehicle for hydrophobic drugs
|
|
CA2652434A1
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized proteins that target ep-cam
|
|
US8998881B2
(en)
*
|
2005-08-10 |
2015-04-07 |
Alza Corporation |
Method for delivering drugs to tissue under microjet propulsion
|
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
ES2272178B1
(es)
*
|
2005-09-19 |
2008-03-16 |
Daniel Serrano Gil |
Una composicion para ser administrada a un mamifero o a un ser humano.
|
|
WO2007041397A2
(en)
*
|
2005-09-30 |
2007-04-12 |
California Pacific Medical Center |
Targeted pharmaceuticals and ligands
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
US20070172520A1
(en)
*
|
2005-11-18 |
2007-07-26 |
University Of South Florida |
Immunotargeting of Nonionic Surfactant Vesicles
|
|
CA2630432A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
EP1962904A2
(en)
*
|
2005-12-22 |
2008-09-03 |
Ivan M. Roitt |
Composition comprising an antigen-recognizing molecule and a lipid-based carrier
|
|
US20080311107A1
(en)
|
2006-02-17 |
2008-12-18 |
Genetech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
|
EP2389948A1
(en)
|
2006-03-23 |
2011-11-30 |
Novartis AG |
Anti-tumor cell antigen antibody therapeutics
|
|
WO2007126455A2
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
|
EP2082645A1
(en)
|
2006-04-19 |
2009-07-29 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
US20070281034A1
(en)
*
|
2006-05-15 |
2007-12-06 |
Kirpotin Dmitri B |
Magnetic microparticles comprising organic substances
|
|
CA2652452C
(en)
|
2006-05-15 |
2018-07-31 |
Sea Lane Biotechnologies, Llc |
Neutralizing antibodies to influenza viruses
|
|
SI2029173T1
(sl)
|
2006-06-26 |
2016-12-30 |
Macrogenics, Inc. |
Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
|
|
US8541190B2
(en)
*
|
2006-06-28 |
2013-09-24 |
Robert M. Weis |
Methods and materials for in vitro analysis and/or use of membrane-associated proteins, portions thereof or variants thereof
|
|
US9683026B2
(en)
|
2006-07-19 |
2017-06-20 |
The Trustees Of The University Of Pennslyvania |
WSX-1/P28 as a target for anti-inflammatory responses
|
|
WO2008013918A2
(en)
|
2006-07-26 |
2008-01-31 |
Myelin Repair Foundation, Inc. |
Cell cycle regulation and differentiation
|
|
WO2008021290A2
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
|
DK2059536T3
(da)
|
2006-08-14 |
2014-04-14 |
Xencor Inc |
Optimerede antistoffer, der er rettet mod cd19
|
|
US20100292090A1
(en)
|
2006-08-25 |
2010-11-18 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
|
CA2670696A1
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
CN101209243B
(zh)
|
2006-12-29 |
2010-12-08 |
石药集团中奇制药技术（石家庄）有限公司 |
一种脂质体药物及其制备方法
|
|
TWI352199B
(en)
*
|
2007-03-02 |
2011-11-11 |
Genentech Inc |
Predicting response to a her inhibitor
|
|
WO2008116347A1
(en)
|
2007-03-26 |
2008-10-02 |
General Regeneratives Limited |
Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
|
|
WO2008150494A1
(en)
|
2007-05-30 |
2008-12-11 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
US9551033B2
(en)
*
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
CA3006428A1
(en)
*
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
|
ES2381788T3
(es)
|
2007-07-16 |
2012-05-31 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
|
RU2557319C2
(ru)
|
2007-07-16 |
2015-07-20 |
Дженентек, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
|
|
JPWO2009020093A1
(ja)
*
|
2007-08-09 |
2010-11-04 |
第一三共株式会社 |
デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
|
|
KR101521668B1
(ko)
|
2007-08-30 |
2015-05-28 |
다이이찌 산쿄 가부시키가이샤 |
항ｅｐｈａ２ 항체
|
|
JP4932940B2
(ja)
|
2007-11-12 |
2012-05-16 |
セラクローン サイエンシーズ， インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
|
DK2808343T3
(da)
|
2007-12-26 |
2019-08-19 |
Xencor Inc |
Fc-varianter med ændret binding til FcRn
|
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
HUE029869T2
(en)
|
2008-01-31 |
2017-04-28 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
US7982012B2
(en)
|
2008-03-10 |
2011-07-19 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus
|
|
WO2009121004A2
(en)
|
2008-03-28 |
2009-10-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to viral antigens
|
|
CN102124344B
(zh)
|
2008-05-16 |
2015-04-01 |
霍夫曼-拉罗奇有限公司 |
生物标记用于评估β7整联蛋白拮抗剂治疗胃肠道炎性病症的用途
|
|
ITMI20081052A1
(it)
*
|
2008-06-10 |
2009-12-11 |
Univ Milano Bicocca |
Liposomi in grado di legare efficacemente il peptide beta-amiloide
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
US8883211B2
(en)
|
2008-07-10 |
2014-11-11 |
Serina Therapeutics, Inc. |
Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
建南德克公司 |
治療進展型多發性硬化症之方法
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
US20120027843A1
(en)
*
|
2009-02-04 |
2012-02-02 |
Tetsuo Minamino |
Hb-egf bound protein complex
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
JP5624114B2
(ja)
|
2009-03-20 |
2014-11-12 |
ジェネンテック， インコーポレイテッド |
抗ｈｅｒ抗体
|
|
WO2010114859A1
(en)
|
2009-04-01 |
2010-10-07 |
Genentech, Inc. |
Treatment of insulin-resistant disorders
|
|
SG174992A1
(en)
|
2009-04-01 |
2011-11-28 |
Genentech Inc |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
|
CN102459340A
(zh)
|
2009-04-23 |
2012-05-16 |
特罗科隆科学有限公司 |
粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
|
|
US8858948B2
(en)
|
2009-05-20 |
2014-10-14 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
CA2761280A1
(en)
|
2009-05-29 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
|
EP3205723A1
(en)
|
2009-06-26 |
2017-08-16 |
i2 Pharmaceuticals, Inc. |
Expression of surrogate light chains
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
|
SG10201408599QA
(en)
|
2009-11-30 |
2015-02-27 |
Genentech Inc |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
|
|
US20120269830A1
(en)
|
2009-12-07 |
2012-10-25 |
Lawrence Horowitz |
Conjugates with improved pharmacokinetic properties
|
|
EP2516468B1
(en)
|
2009-12-23 |
2016-03-02 |
Synimmune GmbH |
Anti-flt3 antibodies and methods of using the same
|
|
US9017669B2
(en)
|
2009-12-28 |
2015-04-28 |
Oncotherapy Science, Inc. |
Anti-CDH3 antibodies and uses thereof
|
|
WO2011091154A2
(en)
*
|
2010-01-21 |
2011-07-28 |
The Regents Of The University Of California |
Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
|
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
|
RU2587619C2
(ru)
|
2010-02-18 |
2016-06-20 |
Дженентек, Инк. |
Антагонисты неурегулина и применение их в лечении злокачественного новообразования
|
|
BR112012020373A8
(pt)
|
2010-02-23 |
2018-01-02 |
Genentech Inc |
anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
|
|
WO2011120134A1
(en)
|
2010-03-29 |
2011-10-06 |
Zymeworks, Inc. |
Antibodies with enhanced or suppressed effector function
|
|
CN107090045A
(zh)
|
2010-05-03 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
|
CA2798273A1
(en)
|
2010-05-04 |
2011-11-10 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
|
AU2011289275A1
(en)
|
2010-08-12 |
2013-02-21 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
|
EP3556396B1
(en)
|
2010-08-31 |
2022-04-20 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
|
AU2011296085A1
(en)
|
2010-09-03 |
2013-03-28 |
Academia Sinica |
Anti-c-Met antibody and methods of use thereof
|
|
TW201307385A
(zh)
|
2010-10-25 |
2013-02-16 |
Genentech Inc |
胃腸炎症和銀屑病以及哮喘的治療
|
|
WO2012099566A1
(en)
|
2010-11-17 |
2012-07-26 |
Sea Lane Biotechnologies, Llc |
Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
KR20140041396A
(ko)
|
2010-12-06 |
2014-04-04 |
메리맥 파마슈티컬즈, 인크. |
안트라사이클린 화학요법제를 포함하는 erbb2-표적 면역리포좀으로의 치료에서 심장독성을 예방하기 위한 용량 및 투여
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
TW201245223A
(en)
|
2011-02-14 |
2012-11-16 |
Theraclone Sciences Inc |
Compositions and methods for the therapy and diagnosis of influenza
|
|
CA2827118A1
(en)
|
2011-02-15 |
2012-08-23 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
WO2012125614A1
(en)
|
2011-03-15 |
2012-09-20 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
CN109734807A
(zh)
|
2011-03-31 |
2019-05-10 |
豪夫迈·罗氏有限公司 |
施用β7整联蛋白拮抗剂的方法
|
|
KR101589135B1
(ko)
|
2011-04-20 |
2016-01-29 |
주식회사 셀앤바이오 |
인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
|
|
EP3403672A1
(en)
|
2011-04-20 |
2018-11-21 |
Medlmmune, LLC |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
|
WO2013003647A2
(en)
|
2011-06-28 |
2013-01-03 |
Sea Lane Biotechnologies, Llc |
Multispecific stacked variable domain binding proteins
|
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
|
WO2013041687A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
|
WO2013063229A1
(en)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
|
EA201490879A1
(ru)
|
2011-10-28 |
2014-08-29 |
Дженентек, Инк. |
Терапевтические комбинации и способы лечения меланомы
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
JP2015500638A
(ja)
|
2011-11-30 |
2015-01-08 |
ジェネンテック， インコーポレイテッド |
癌におけるｅｒｂｂ３変異
|
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
|
AU2012352454A1
(en)
|
2011-12-15 |
2014-07-17 |
The University Of Chicago |
Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
|
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
|
CN106727329B
(zh)
|
2012-02-17 |
2020-11-03 |
效思因公司 |
热敏纳米颗粒制剂及其制备方法
|
|
MX353382B
(es)
|
2012-03-01 |
2018-01-10 |
Amgen Res Munich Gmbh |
Moleculas de union polipeptido de larga duracion.
|
|
PT2825157T
(pt)
|
2012-03-16 |
2018-12-14 |
Merck Patent Gmbh |
Lípidos de aminoácidos
|
|
AU2013231638B2
(en)
|
2012-03-16 |
2017-10-12 |
Merck Patent Gmbh |
Targeting aminoacid lipids
|
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
|
CN104334724B
(zh)
|
2012-04-09 |
2020-09-01 |
第一三共株式会社 |
抗-fgfr2抗体
|
|
RU2682451C2
(ru)
|
2012-04-27 |
2019-03-19 |
Дайичи Санкио Компани, Лимитед |
Антитела к robo4
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
SG10201701165TA
(en)
|
2012-08-14 |
2017-03-30 |
Univ Nanyang Tech |
Angiopoietin-like 4 antibody and a method of its use in cancer treatment
|
|
RU2015112024A
(ru)
|
2012-10-05 |
2016-11-27 |
Дженентек, Инк. |
Способы диагностики и лечения воспалительного заболевания кишечника
|
|
TR201908531T4
(tr)
|
2012-11-20 |
2019-08-21 |
Arbutus Biopharma Corp |
Terapöti̇k kullanim i̇çi̇n li̇pozom kapsüllü vi̇nkri̇sti̇ni̇n preparasyonuna yöneli̇k geli̇şti̇ri̇lmi̇ş yöntem
|
|
JP6998646B2
(ja)
|
2012-11-30 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
|
|
AU2013355337B2
(en)
*
|
2012-12-03 |
2018-07-12 |
Merrimack Pharmaceuticals, Inc. |
Combination therapy for treating HER2-positive cancers
|
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
US11156608B2
(en)
|
2013-03-15 |
2021-10-26 |
The Trustees Of The University Of Pennsylvania |
Method for the site-specific covalent cross-linking of antibodies to surfaces
|
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
|
DK2970449T3
(da)
|
2013-03-15 |
2019-11-25 |
Amgen Res Munich Gmbh |
Enkeltkædede bindingsmolekyler, der omfatter n-terminal abp
|
|
CN105143876B
(zh)
|
2013-03-27 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
|
|
WO2014190356A2
(en)
|
2013-05-24 |
2014-11-27 |
Amplimmune, Inc. |
Anti-b7-h5 antibodies and their uses
|
|
US9884126B2
(en)
|
2013-05-31 |
2018-02-06 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
|
HUE050451T2
(hu)
|
2013-05-31 |
2020-12-28 |
Genentech Inc |
Anti-fal-teichonsav antitestek és konjugátumok
|
|
US10093978B2
(en)
|
2013-08-12 |
2018-10-09 |
Genentech, Inc. |
Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
|
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
|
JP6509735B2
(ja)
|
2013-10-08 |
2019-05-08 |
第一三共株式会社 |
抗ｆｇｆｒ２抗体と他剤の組合せ
|
|
WO2015148809A1
(en)
|
2014-03-27 |
2015-10-01 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
|
MX377344B
(es)
|
2014-07-31 |
2025-03-07 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas.
|
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
WO2016022723A1
(en)
|
2014-08-05 |
2016-02-11 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
|
|
JP6751393B2
(ja)
|
2014-12-03 |
2020-09-02 |
ジェネンテック， インコーポレイテッド |
抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用
|
|
JP6742314B2
(ja)
|
2014-12-03 |
2020-08-19 |
ジェネンテック， インコーポレイテッド |
抗黄色ブドウ球菌抗体リファマイシン複合体及びその使用
|
|
EP3250927B1
(en)
|
2015-01-28 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Gene expression markers and treatment of multiple sclerosis
|
|
HUE049791T2
(hu)
|
2015-02-19 |
2020-10-28 |
Compugen Ltd |
PVRIG elleni antitestek és alkalmazási eljárások
|
|
US10550173B2
(en)
|
2015-02-19 |
2020-02-04 |
Compugen, Ltd. |
PVRIG polypeptides and methods of treatment
|
|
MX2017010336A
(es)
|
2015-02-26 |
2017-12-20 |
Genentech Inc |
Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
|
|
DK3283524T3
(da)
|
2015-04-17 |
2023-05-30 |
Amgen Res Munich Gmbh |
BISPECIFIKKE ANTISTOFKONSTRUKTIONER MOD CDH3 og CD3
|
|
WO2016183387A1
(en)
|
2015-05-12 |
2016-11-17 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for making antibody conjugates
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
HK1255200A1
(zh)
|
2015-05-29 |
2019-08-09 |
F. Hoffmann-La Roche Ag |
癌症中pd-l1启动子甲基化
|
|
CA2991980A1
(en)
|
2015-07-13 |
2017-01-19 |
Compugen Ltd. |
Hide1 compositions and methods
|
|
TWI678213B
(zh)
|
2015-07-22 |
2019-12-01 |
美商史倍壯製藥公司 |
用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
Dll3及cd3抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EP3337467B1
(en)
|
2015-08-20 |
2020-12-09 |
Ipsen Biopharm Ltd. |
Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
|
|
TW202243677A
(zh)
|
2015-08-21 |
2022-11-16 |
英商益普生生物製藥有限公司 |
使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
|
|
ES3007182T3
(en)
|
2015-10-06 |
2025-03-19 |
Hoffmann La Roche |
Method for treating multiple sclerosis
|
|
CN108366965B
(zh)
|
2015-10-16 |
2021-10-01 |
易普森生物制药有限公司 |
稳定喜树碱药物组合物
|
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
|
JP7227007B2
(ja)
|
2015-12-02 |
2023-02-21 |
ストサイエンシス， インコーポレイテッド |
グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
|
|
KR102803158B1
(ko)
|
2015-12-02 |
2025-05-08 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
|
|
JOP20170017B1
(ar)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
CN114716557A
(zh)
|
2016-02-03 |
2022-07-08 |
安进研发（慕尼黑）股份有限公司 |
Psma和cd3双特异性t细胞接合抗体构建体
|
|
CN116063544A
(zh)
|
2016-02-03 |
2023-05-05 |
安进研发（慕尼黑）股份有限公司 |
Bcma和cd3双特异性t细胞接合抗体构建体
|
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
|
EP3468997B1
(en)
|
2016-06-08 |
2023-09-13 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
|
EP3487521A4
(en)
|
2016-07-21 |
2020-07-01 |
Emory University |
ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
|
|
CA3036829A1
(en)
|
2016-09-14 |
2018-03-22 |
The Trustees Of The University Of Pennsylvania |
Proximity-based sortase-mediated protein purification and ligation
|
|
US20190300607A1
(en)
|
2016-10-12 |
2019-10-03 |
Daiichi Sankyo Company, Limited |
Composition containing anti-robo4 antibody and other agents
|
|
AU2017354903B2
(en)
|
2016-11-02 |
2023-04-13 |
Ipsen Biopharm Ltd. |
Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
|
|
LT3561057T
(lt)
|
2016-12-22 |
2025-09-25 |
Daiichi Sankyo Company, Limited |
Anti-cd3 antikūnas ir molekulė, kurios sudėtyje yra minėtas antikūnas
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
AU2018218753A1
(en)
|
2017-02-07 |
2019-09-26 |
Daiichi Sankyo Company, Limited |
Anti-GPRC5D antibody and molecule containing same
|
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
|
TWI782000B
(zh)
|
2017-03-30 |
2022-11-01 |
日商第一三共股份有限公司 |
抗ｇｐｒ２０抗體、其製造方法及其應用
|
|
WO2018200742A1
(en)
|
2017-04-25 |
2018-11-01 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
|
TWI868050B
(zh)
|
2017-05-05 |
2025-01-01 |
美商安進公司 |
用於改良儲存及投與之包含雙特異性抗體構築體之醫藥組成物
|
|
US11530273B2
(en)
|
2017-05-23 |
2022-12-20 |
Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
|
|
WO2018222685A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
|
AU2018277838C1
(en)
|
2017-05-31 |
2025-08-07 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
|
EP3655430A1
(en)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
|
EP3693012A4
(en)
|
2017-10-05 |
2021-07-21 |
Daiichi Sankyo Company, Limited |
CYTOTOXIC T-CELL DEPLOYMENT COMPOSITION
|
|
WO2019118426A1
(en)
|
2017-12-11 |
2019-06-20 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
|
|
WO2019197607A1
(en)
|
2018-04-13 |
2019-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fc-engineered anti-human ige antibodies and methods of use
|
|
EP3788071A1
(en)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
|
AU2019269588A1
(en)
*
|
2018-05-15 |
2020-12-10 |
Flagship Pioneering Innovations Vi, Llc |
Pathogen control compositions and uses thereof
|
|
MX2021003976A
(es)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecificos.
|
|
EP4272731A3
(en)
|
2018-12-11 |
2024-02-14 |
Disruption Labs Inc. |
Compositions for the delivery of therapeutic agents and methods of use and making thereof
|
|
CA3137494A1
(en)
|
2019-06-13 |
2020-12-17 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
|
US20220411511A1
(en)
|
2019-09-26 |
2022-12-29 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
|
US20220356248A1
(en)
|
2019-10-09 |
2022-11-10 |
Stcube & Co |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
|
|
IL296601A
(en)
|
2020-03-19 |
2022-11-01 |
Amgen Inc |
Antibodies against mucin 17 and their uses
|
|
CA3194386A1
(en)
|
2020-10-06 |
2022-04-14 |
Ying Ding |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
|
JP2023549116A
(ja)
|
2020-11-06 |
2023-11-22 |
アムジエン・インコーポレーテツド |
選択性が増大した多標的二重特異性抗原結合分子
|
|
WO2022210485A1
(ja)
|
2021-03-29 |
2022-10-06 |
第一三共株式会社 |
安定な多重特異性分子及びその利用
|
|
JP2024518369A
(ja)
|
2021-05-06 |
2024-05-01 |
アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング |
増殖性疾患で使用されるｃｄ２０及びｃｄ２２標的化抗原結合分子
|
|
US20230115257A1
(en)
|
2021-05-17 |
2023-04-13 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
US20220372114A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
EP4410277A4
(en)
*
|
2021-09-30 |
2025-10-22 |
Nof Corp |
LIPID NANOPARTICLES WITH CELLULAR DIRECTIONALITY
|
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
|
CN121293357A
(zh)
|
2022-08-22 |
2026-01-09 |
雅博得乐医疗公司 |
Dll3结合分子及其用途
|
|
EP4587474A2
(en)
|
2022-09-14 |
2025-07-23 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
|
UY40797A
(es)
|
2023-06-14 |
2024-12-31 |
Amgen Inc |
Moléculas captadoras de enmascaramiento de células t
|
|
WO2026005603A1
(en)
|
2024-06-25 |
2026-01-02 |
ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) |
A method for preparing liposomes
|